BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15885860)

  • 1. Myelodysplasic syndromes: a comprehensive review.
    Catenacci DV; Schiller GJ
    Blood Rev; 2005 Nov; 19(6):301-19. PubMed ID: 15885860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refractory anemia and the myelodysplastic syndromes.
    Lawrence LW
    Clin Lab Sci; 2004; 17(3):178-86. PubMed ID: 15314893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelodysplasia: when to treat and how.
    Larson RA
    Best Pract Res Clin Haematol; 2006; 19(2):293-300. PubMed ID: 16516126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombocytopenia in myelodysplastic syndromes and myelofibrosis.
    Boruchov AM
    Semin Hematol; 2009 Jan; 46(1 Suppl 2):S37-43. PubMed ID: 19245933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
    J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome.
    de Lima M; Giralt S
    Semin Hematol; 2006 Apr; 43(2):107-17. PubMed ID: 16616044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous stem cell transplantation in myelodysplastic syndromes.
    de Witte T; Suciu S; Brand R; Muus P; Kröger N
    Semin Hematol; 2007 Oct; 44(4):274-7. PubMed ID: 17961727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic growth factors in the treatment of acquired bone marrow failure states.
    Marsh JC; Ganser A; Stadler M
    Semin Hematol; 2007 Jul; 44(3):138-47. PubMed ID: 17631178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supportive care including growth factors in myelodysplastic syndromes.
    Gardin C; Fenaux P
    Rev Clin Exp Hematol; 2004 Dec; 8(2):E3. PubMed ID: 16027101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
    J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolution of hematopoietic SCT in myelodysplastic syndrome.
    Kindwall-Keller T; Isola LM
    Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndrome in children and adolescents.
    Niemeyer CM; Baumann I
    Semin Hematol; 2008 Jan; 45(1):60-70. PubMed ID: 18179970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS).
    List AF
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S31-5. PubMed ID: 16085015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the therapy for myelodysplastic syndrome.
    Kasner MT; Luger SM
    Am J Hematol; 2009 Mar; 84(3):177-86. PubMed ID: 19195035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.
    Abdelhameed A; Pond GR; Mitsakakis N; Brandwein J; Chun K; Gupta V; Kamel-Reid S; Lipton JH; Minden MD; Schimmer A; Schuh A; Yee K; Messner HA
    Cancer; 2008 Apr; 112(7):1513-21. PubMed ID: 18286528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the Myelodysplastic Syndromes.
    Kouides PA; Bennett JM
    Oncologist; 1997; 2(6):389-401. PubMed ID: 10388074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
    Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
    Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic growth factors in myelodysplastic syndromes.
    Blinder VS; Roboz GJ
    Curr Hematol Rep; 2003 Nov; 2(6):453-8. PubMed ID: 14561388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.